VKTX - Latest News

Viking Therapeutics, Inc. (VKTX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $3.68B. Beta to the broader market is 0.71.

The article list below shows the most recent VKTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent VKTX Headlines

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?

zacks.com - May 14, 2026

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders

247wallst.com - May 14, 2026

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.

Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead

zacks.com - May 13, 2026

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

prnewswire.com - May 12, 2026

Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all V

Viking Therapeutics: Market Betting On Big Upside Through 2030

seekingalpha.com - May 5, 2026

Viking Therapeutics is making really solid pipeline progress and possesses a unique dual agonist approach in the fast-growing obesity drugs market. V

How News Affects VKTX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VKTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked VKTX news questions

What is the latest VKTX news headline?

The most recent VKTX headline (May 14, 2026) is "Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the VKTX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What VKTX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual VKTX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.